

1. Record Nr.	UNINA9910830282803321
Titolo	Parkinson disease [[electronic resource] ] : a health policy perspective / / edited by Wayne Martin [et al.]
Pubbl/distr/stampa	Weinheim, : Wiley-VCH Verlag GmbH & Co., c2010
ISBN	1-282-55040-3 9786612550409 3-527-62948-3 3-527-62949-1
Descrizione fisica	1 online resource (362 p.)
Collana	Health Care and Disease Management
Altri autori (Persone)	MartinWayne
Disciplina	616.833 616.83306
Soggetti	Parkinson's disease Medical policy
Lingua di pubblicazione	Inglese
Formato	Materiale a stampa
Livello bibliografico	Monografia
Note generali	Description based upon print version of record.
Nota di bibliografia	Includes bibliographical references and index.
Nota di contenuto	Parkinson Disease: A Health Policy Perspective; Contents; Preface; Summary and Policy Considerations; List of Contributors; Part I: Parkinson Disease - Diagnosis and Treatment; 1: Parkinson Disease; 1.1: Patient Burden; 1.2: Characteristics of Parkinson Disease; 1.3: Diagnosis of Parkinson Disease; 1.4: Treatment for Parkinson Disease; References; 2: Clinical Features of Parkinson Disease; 2.1: Introduction; 2.2: Cardinal Features; 2.3: Differential Diagnosis; 2.3.1: Essential Tremor; 2.3.2: Progressive Supranuclear Palsy; 2.3.3: Multiple System Atrophy 2.3.4: Cortico-Basal Ganglionic Degeneration2.3.5: Dementia with Lewy Bodies; 2.3.6: Vascular Parkinsonism; 2.4: Non-Dopaminergic Features of PD; 2.4.1: Sleep Disturbances; 2.4.2: Olfaction; 2.4.3: Dysautonomia; 2.4.4: Neuropsychiatric Features; 2.4.4.1: Dementia; 2.4.4.2: Depression; 2.5: Natural History; 2.6: Conclusions; References; 3: Current Approaches to the Management of Parkinson Disease; 3.1: Introduction; 3.2: Pharmacologic Treatment; 3.2.1: Symptomatic Therapy; 3.2.1.1: Levodopa; 3.2.1.2: Levodopa-Induced Motor Complications; 3.2.1.3: Catechol-O-Methyl Transferase (COMT)

## Inhibitors

3.2.1.4: Monoamine Oxidase B (MAO-B) Inhibitors 3.2.1.5: Dopamine Agonists; 3.2.1.6: Managing Drug-Induced Adverse Events; 3.2.2: Neuroprotective Therapy; 3.2.3: Surgical Treatment; 3.2.4: Non-Pharmacologic Treatment; 3.3: Nursing; 3.4: Rehabilitation; 3.4.1: Physical Therapy; 3.4.2: Occupational Therapy; 3.4.3: Speech Therapy; 3.5: Nutrition; 3.6: Psychosocial Issues; 3.7: Conclusions; References; 4: Treatment of Non-Motor Symptoms of Parkinson Disease; 4.1: Sleep Disturbances; 4.2: Autonomic Dysfunction; 4.2.1: Orthostatic (Postural) Hypotension; 4.2.2: Urinary Dysfunction; 4.2.3: Gastrointestinal Dysfunction; 4.2.3.1: Dysphagia; 4.2.3.2: Gastroparesis; 4.2.3.3: Constipation; 4.2.3.4: Anorectal Dysfunction; 4.2.4: Weight Loss; 4.2.5: Sweating Disturbances; 4.2.6: Sexual Dysfunction; 4.2.7: Sialorrhea; 4.2.8: Dyspnea; 4.3: Neuropsychiatric Problems; 4.3.1: Depression; 4.3.2: Anxiety; 4.3.3: Apathy; 4.3.4: Medication-Related Psychiatric Problems; 4.3.5: Impulse Control Disorders; 4.3.6: Dopamine Dysregulation Syndrome; 4.3.7: Punding Behavior; 4.3.8: Hypersexuality; 4.3.9: Dementia; 4.3.10: Psychosis; 4.4: Sensory Symptoms and Pain; 4.4.1: Pain; 4.4.2: Olfactory Dysfunction; 4.5: Other Problems; 4.5.1: Eye Movement Abnormalities; 4.5.2: Fatigue; 4.6: Non-Motor Fluctuations; 4.7: Conclusions; References; 5: Palliative Care and End-of-Life Issues with Parkinson Disease; 5.1: Challenges in Advanced-Stage PD; 5.2: The Most Common Causes of Death in PD; 5.3: Specific Problems in the Advanced-PD Patient; 5.3.1: Pain; 5.3.2: Cognitive Decline; 5.3.3: Other Psychiatric Complications; 5.3.4: Speech and Swallowing Difficulties; 5.3.5: Bowel and Bladder Dysfunction; 5.3.6: Sleep Disturbances; 5.4: Caregiver Burden; 5.4.1: Placement in Long-Term Care Facilities

---

### Sommario/riassunto

Part of the successful Institute of Health Economics (IHE) book series, this handbook and ready reference adopts a unique approach in combining policy recommendations with specific treatment options for Parkinson patients. The first part of the book deals with the clinical, medical, social and economical aspects of Parkinson Disease. These ten chapters include the latest diagnosis and treatment options for patients, the economical consequences, social and ethical implications and end-of life issues. The second part of the book essentially covers a large-scale case study on Parkinson in Alber

---